MCID: PNL012
MIFTS: 58

Penile Cancer

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Penile Cancer

MalaCards integrated aliases for Penile Cancer:

Name: Penile Cancer 12 36 14
Penis Carcinoma 12 14 69
Penile Neoplasms 41 69
Penile Neoplasm 12 14
Malignant Neoplasm of Body of Penis 12
Malignant Neoplasm of Penis 69
Malignant Penile Tumor 12
Carcinoma of Penis 12
Neoplasm of Penis 12
Penile Carcinoma 12
Penile Tumor 12
Penile Ca 12
Ca Penis 12

Classifications:



Summaries for Penile Cancer

Disease Ontology : 12 A penile cancer that is located in the skin or tissues of the penis.

MalaCards based summary : Penile Cancer, also known as penis carcinoma, is related to anogenital venereal wart and papilloma. An important gene associated with Penile Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Viral carcinogenesis and Endometrial cancer. The drugs Fentanyl and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include the skin or tissues of the penis, lymph node and skin, and related phenotypes are cardiovascular system and integument

Wikipedia : 72 Penile cancer is a malignant growth found on the skin or in the tissues of the penis. Around 95% of... more...

Related Diseases for Penile Cancer

Diseases in the Penile Cancer family:

Penile Cancer, Adult

Diseases related to Penile Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 anogenital venereal wart 29.9 CDKN2A TP53
2 papilloma 29.9 CCND1 CDKN2A TP53
3 squamous cell carcinoma 29.5 CCND1 CDKN2A EGFR HRAS TP53
4 cervical cancer 29.0 CDKN2A HRAS TP53
5 adenocarcinoma 29.0 CCND1 CDKN2A EGFR HRAS TP53
6 bladder cancer 28.4 CCND1 CDKN2A EGFR HRAS IFNA2 TP53
7 penile cancer, adult 12.1
8 penis carcinoma in situ 12.1
9 penile cancer, childhood 12.0
10 penis squamous cell carcinoma 11.5
11 penis verrucous carcinoma 11.0
12 penis basaloid carcinoma 11.0
13 penis papillary carcinoma 11.0
14 brain ependymoma 10.5 EGFR TP53
15 brain stem glioma 10.5 EGFR TP53
16 non-proliferative fibrocystic change of the breast 10.5 CCND1 TP53
17 paronychia 10.4 EGFR HRAS
18 synchronous bilateral breast carcinoma 10.4 CCND1 TP53
19 microglandular adenosis 10.4 EGFR TP53
20 pulmonary blastoma 10.4 EGFR TP53
21 brain stem astrocytic neoplasm 10.4 CDKN2A TP53
22 malignant peritoneal mesothelioma 10.4 CDKN2A EGFR
23 pleomorphic carcinoma 10.4 EGFR TP53
24 lung adenoid cystic carcinoma 10.4 EGFR HRAS
25 cll/sll 10.4 CCND1 TP53
26 squamous cell carcinoma of the oropharynx 10.4 CDKN2A TP53
27 anaplastic oligodendroglioma 10.4 CDKN2A EGFR
28 breast papillomatosis 10.4 CCND1 CDKN2A
29 gastric adenosquamous carcinoma 10.4 CDKN2A EGFR
30 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
31 tonsil squamous cell carcinoma 10.4 CCND1 CDKN2A
32 lymphoid interstitial pneumonia 10.4 CRP TP53
33 bartholin's gland benign neoplasm 10.4 CDKN2A TP53
34 bowenoid papulosis 10.4 CCND1 CDKN2A
35 bladder carcinoma in situ 10.3 CDKN2A TP53
36 skin carcinoma in situ 10.3 CCND1 CDKN2A
37 anal squamous cell carcinoma 10.3 CDKN2A TP53
38 endometrial squamous cell carcinoma 10.3 CCND1 CDKN2A
39 thyroid lymphoma 10.3 CDKN2A TP53
40 recurrent respiratory papillomatosis 10.3 EGFR IFNA2
41 vulva squamous cell carcinoma 10.3 CDKN2A TP53
42 gliomatosis cerebri 10.3 EGFR TP53
43 bone squamous cell carcinoma 10.3 CDKN2A TP53
44 megaesophagus 10.3 CDKN2A TP53
45 scrotal carcinoma 10.3 CDKN2A TP53
46 soft tissue sarcoma 10.3 EGFR TP53
47 conjunctival squamous cell carcinoma 10.3 IFNA2 TP53
48 glycogen-rich clear cell breast carcinoma 10.3 CDKN2A TP53
49 melanomatosis 10.3 CDKN2A HRAS
50 hidradenocarcinoma 10.3 CCND1 EGFR TP53

Graphical network of the top 20 diseases related to Penile Cancer:



Diseases related to Penile Cancer

Symptoms & Phenotypes for Penile Cancer

MGI Mouse Phenotypes related to Penile Cancer:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.92 HRAS SCN10A TP53 APP CCND1 CDKN2A
2 integument MP:0010771 9.8 HRAS SCN10A TP53 APP CCND1 CDKN2A
3 neoplasm MP:0002006 9.55 EGFR HRAS TP53 CCND1 CDKN2A
4 no phenotypic analysis MP:0003012 9.43 HRAS SCN10A TP53 APP CDKN2A EGFR
5 respiratory system MP:0005388 9.1 EGFR HRAS SCN10A TP53 CCND1 CDKN2A

Drugs & Therapeutics for Penile Cancer

Drugs for Penile Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
3
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
4
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
6 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
7 Liver Extracts Phase 3,Phase 2,Phase 1
8 Adjuvants, Anesthesia Phase 3
9 Analgesics Phase 3,Phase 2
10 Analgesics, Opioid Phase 3
11 Anesthetics Phase 3
12 Anesthetics, General Phase 3
13 Anesthetics, Intravenous Phase 3
14 Central Nervous System Depressants Phase 3,Phase 2
15 Narcotics Phase 3
16 Peripheral Nervous System Agents Phase 3,Phase 2
17 Albumin-Bound Paclitaxel Phase 3,Phase 2
18 Alkylating Agents Phase 3,Phase 2,Phase 1
19 Antimitotic Agents Phase 3,Phase 2
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
21 Isophosphamide mustard Phase 3,Phase 2 0
22 Cola Nutraceutical Phase 3,Phase 2,Phase 1
23
Indinavir Approved Phase 2 150378-17-9 5362440
24
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
25
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
26
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
27
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
28
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
29
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
30
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
31
Pembrolizumab Approved Phase 2 1374853-91-4
32
Daratumumab Approved Phase 1, Phase 2 945721-28-8
33
nivolumab Approved Phase 1, Phase 2 946414-94-4
34
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
35
Vinblastine Approved Phase 2 865-21-4 241903 13342
36
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538
37
Camptothecin Experimental Phase 2 7689-03-4
38
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
39 Anti-HIV Agents Phase 2,Phase 1
40 Anti-Infective Agents Phase 2,Phase 1
41 Anti-Retroviral Agents Phase 2,Phase 1
42 Antiviral Agents Phase 2,Phase 1
43 Cytochrome P-450 CYP3A Inhibitors Phase 2
44 Cytochrome P-450 Enzyme Inhibitors Phase 2
45 HIV Protease Inhibitors Phase 2
46
protease inhibitors Phase 2
47 interferons Phase 2,Phase 1
48 topoisomerase I inhibitors Phase 2
49 Topoisomerase Inhibitors Phase 2
50 Vaccines Phase 2,Phase 1

Interventional clinical trials:

(show all 47)

# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Not yet recruiting NCT02305654 Phase 3 Paclitaxel;Ifosfamide;Cisplatin
3 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
4 Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer Completed NCT00066391 Phase 2 cisplatin;irinotecan hydrochloride
5 Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis Completed NCT00512096 Phase 2 Ifosfamide;Paclitaxel (Taxol);Cisplatin
6 A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis Completed NCT03114254 Phase 2 Cabazitaxel
7 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Completed NCT01209325 Phase 2
8 Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer Completed NCT00002506 Phase 2 isotretinoin
9 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
10 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
11 Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (AFU-GETUG 25) Recruiting NCT02817958 Phase 2 Chemotherapie TIP
12 Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis Recruiting NCT01728233 Phase 2 Dacomitinib
13 Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Recruiting NCT02837042 Phase 2 Pembrolizumab
14 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;BMS-986016;Daratumumab
15 HPV Anti-CD40 RNA Vaccine Recruiting NCT03418480 Phase 1, Phase 2 HPV vaccine
16 M7824 in Subjects With HPV Associated Malignancies Recruiting NCT03427411 Phase 2 M7824
17 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
18 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
19 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
20 Avelumab With Valproic Acid in Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
21 A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP) Active, not recruiting NCT02057913 Phase 2 Vinflunine
22 A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy Not yet recruiting NCT03391479 Phase 2 Avelumab
23 S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) Terminated NCT00058448 Phase 2 docetaxel
24 Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG) Terminated NCT02279576 Phase 2 Pazopanib;Paclitaxel
25 Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) Withdrawn NCT02014831 Phase 2 Cetuximab;TIP
26 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
27 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
28 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
29 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00083213 Phase 1
30 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00082823 Phase 1
31 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Completed NCT00003704 Phase 1 capecitabine
32 Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers Completed NCT02526316 Phase 1
33 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
34 HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA Recruiting NCT02379520 Phase 1 Cytoxan;Fludarabine
35 Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET] Unknown status NCT02104063
36 Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer Completed NCT01526486
37 Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents Completed NCT02236273
38 Cancer in Patients With Gabapentin (GPRD) Completed NCT01236053 Gabapentin prescriptions
39 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
40 Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients Completed NCT00253383
41 HOUSTON - HPV-related Oropharyngeal and Uncommon Cancers Screening Trial Of Men Recruiting NCT02897427
42 Laser Fluorescence in Cancer Surgical Treatment Recruiting NCT03021200
43 Development of Diagnostics and Treatment of Urological Cancers Recruiting NCT02994758
44 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
45 Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy Active, not recruiting NCT00955929 Placebo QHS and sildenafil and questionnaires;Sildenafil and questionnaire;Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
46 Engaging Patients and Providers in Collaborative Communication on HPV Vaccination (EPICC-HPV) Not yet recruiting NCT03267251
47 Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention Not yet recruiting NCT03346915

Search NIH Clinical Center for Penile Cancer

Cochrane evidence based reviews: penile neoplasms

Genetic Tests for Penile Cancer

Anatomical Context for Penile Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Penile Cancer:

18
The Skin Or Tissues Of The Penis

MalaCards organs/tissues related to Penile Cancer:

38
Lymph Node, Skin, T Cells, Liver, Brain, Prostate, Neutrophil

Publications for Penile Cancer

Articles related to Penile Cancer:

(show top 50) (show all 429)
# Title Authors Year
1
Penile-sparing modalities in the management of low-stage penile cancer. ( 29416267 )
2018
2
Penile cancer sparing surgery: The balance between oncological cure and functional preservation. ( 29306557 )
2018
3
Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer. ( 29433986 )
2018
4
Prognostic factors in patients with penile cancer after surgical management. ( 29299663 )
2018
5
Thulium-yttrium-aluminium-garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life. ( 29197968 )
2018
6
Comparative Study of Video Endoscopic Inguinal Lymphadenectomy Through a Hypogastric vs Leg Subcutaneous Approach for Penile Cancer. ( 29256632 )
2018
7
Increased Risk of Penile Cancer among Men Working in Agriculture ( 29374407 )
2018
8
The Patterns of Practice and Outcomes of Penile Cancer in Ontario. ( 28057403 )
2017
9
Subclassification of pN3 staging systems for penile cancer: Proposal for modification of the current TNM classification. ( 28578871 )
2017
10
Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. ( 29288008 )
2017
11
Advanced penile cancer with iliac lymph node involvement treated with radiation and concurrent gemcitabine. ( 28411892 )
2017
12
Contemporary management of patients with penile cancer and lymph node metastasis. ( 28401957 )
2017
13
Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence Free Survival for Patients with Penile Cancer. ( 28652123 )
2017
14
Advancements in staging and imaging for penile cancer. ( 28937510 )
2017
15
Proposal for reclassification of N staging system in penile cancer patients, based on number of positive lymph nodes. ( 29285831 )
2017
16
Serum biomarkers to predict risk of testicular and penile cancer in AMORIS. ( 28900475 )
2017
17
Contemporary survival trends in penile cancer: Results from the National Cancer Database. ( 28882672 )
2017
18
Differences in Survival by Receipt of Lymph Node Dissection inA Patients with Invasive Penile Cancer: Results from NCDB. ( 29248557 )
2017
19
Immunotherapy for penile cancer. ( 28883996 )
2017
20
Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. ( 28666722 )
2017
21
Long-term trends in incidence and survival of penile cancer in France. ( 28898817 )
2017
22
Robotic inguinal lymphadenectomy for penile cancer: the why, how, and what. ( 29184779 )
2017
23
Clinical scenarios for neoadjuvant chemotherapy of squamous penile cancer that is clinically node positive. ( 29184781 )
2017
24
Bilateral pelvic lymph node dissection for Chinese patients with penile cancer: a multicenter collaboration study. ( 27771796 )
2017
25
National Trends and Predictors of Locally Advanced Penile Cancer in the United States (1998-2012). ( 28866244 )
2017
26
Clinicopathologic Characteristics and Treatment Outcomes of Penile Cancer. ( 28459145 )
2017
27
Role of perioperative dynamic sentinel node biopsy for cN0 penile cancer management: experience from an Italian tertiary referral center. ( 29192738 )
2017
28
Analysis of Knowledge Level in Brazilian Students about Human Papillomavirus Infection and Development of Penile Cancer ( 28612588 )
2017
29
Validation of predictors for lymph node status in penile cancer: Results from a population-based cohort. ( 29319487 )
2017
30
The role of PET/CT imaging in penile cancer. ( 29184780 )
2017
31
Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer. ( 28118628 )
2017
32
Comparison of efficacy between brachytherapy and penectomy in patients with penile cancer: a meta-analysis. ( 29245993 )
2017
33
E2F1 Signalling is Predictive of Chemoresistance and Lymphogenic Metastasis in Penile Cancer: A Pilot Functional Study Reveals New Prognostic Biomarkers. ( 28753861 )
2017
34
Contemporary role of radiotherapy in the management of penile cancer. ( 29184783 )
2017
35
Identifying Psychosocial Distress and Stressors Using Distress-screening Instruments in Patients With Localized and Advanced Penile Cancer. ( 28499559 )
2017
36
Exophytic papillary penile cancer. ( 28687155 )
2017
37
Surgical treatment of advanced penile cancer. ( 28493019 )
2017
38
Surveillance strategies in the management of penile cancer. ( 29184784 )
2017
39
Human papillomavirus, Epstein-Barr virus, and methylation status of p16(ink4a) in penile cancer. ( 28403538 )
2017
40
Current Management Strategy for Penile Cancer and Future Directions. ( 28664471 )
2017
41
Racial disparity and survival outcomes between African-American and Caucasian American men with penile cancer. ( 29281853 )
2017
42
Penile cancer metastasizing to the breast: a case report. ( 26961850 )
2016
43
Centralization of Penile Cancer Management in the United States: A Combined Analysis of the American Board of Urology and National Cancer Data Base. ( 26827845 )
2016
44
Expression of Programmed Death Ligand 1 in Penile Cancer Is of Prognostic Value and Associated with HPV Status. ( 27697578 )
2016
45
Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies? ( 27738628 )
2016
46
15 Years of penile cancer management in the United States: An analysis of the use of partial penectomy for localized disease and chemotherapy in the metastatic setting. ( 27495001 )
2016
47
Glansectomy and Split-thickness Skin Graft for Penile Cancer. ( 27746062 )
2016
48
Penile cancer: Welcome changes in disease management and remaining challenges. ( 27797359 )
2016
49
Prospective study comparing Videoendoscopic radical Inguinal Lymph node dissection (VEILND) with Open radical inguinal lymphnode dissection (OILND) for penile cancer over an 8 year period. ( 27628265 )
2016
50
Emerging Systemic Therapies for the Management of Penile Cancer. ( 27717434 )
2016

Variations for Penile Cancer

Cosmic variations for Penile Cancer:

9 (show all 23)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM12475 CDKN2A skin,penis,carcinoma,squamous cell carcinoma c.238C>T p.R80* 15
2 COSM11491 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.743G>C p.R248P 7
3 COSM10656 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.742C>T p.R248W 7
4 COSM10660 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.818G>A p.R273H 7
5 COSM45765 TP53 skin,leg,carcinoma,squamous cell carcinoma c.987C>A p.T329T 7
6 COSM10863 TP53 skin,leg,carcinoma,squamous cell carcinoma c.833C>T p.P278L 7
7 COSM45114 TP53 skin,leg,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 7
8 COSM1735722 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.298G>A p.G100R 7
9 COSM1735721 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.297G>A p.W99* 7
10 COSM214151 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.585G>A p.W195* 7
11 COSM1731707 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.1789C>T p.Q597* 7
12 COSM5316 PTEN skin,NS,carcinoma,Merkel cell carcinoma c.439A>T p.K147* 7
13 COSM766 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1636C>A p.Q546K 7
14 COSM27133 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1633G>C p.E545Q 7
15 COSM760 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1624G>A p.E542K 7
16 COSM763 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1633G>A p.E545K 7
17 COSM776 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.3140A>T p.H1047L 7
18 COSM249774 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.56G>A p.R19K 7
19 COSM573 NRAS skin,scalp,carcinoma,squamous cell carcinoma c.38G>A p.G13D 7
20 COSM521 KRAS skin,scalp,carcinoma,squamous cell carcinoma c.35G>A p.G12D 7
21 COSM554 KRAS skin,scalp,carcinoma,squamous cell carcinoma c.183A>C p.Q61H 7
22 COSM499 HRAS skin,trunk,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 7
23 COSM498 HRAS skin,trunk,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 7

Expression for Penile Cancer

Search GEO for disease gene expression data for Penile Cancer.

Pathways for Penile Cancer

Pathways related to Penile Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203

Pathways related to Penile Cancer according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 CCND1 CDKN2A EGFR HRAS TP53
2
Show member pathways
12.81 CCND1 EGFR HRAS IFNA2 TP53
3
Show member pathways
12.57 CCND1 CDKN2A EGFR HRAS TP53
4 12.52 CCND1 CDKN2A EGFR HRAS IFNA2 TP53
5
Show member pathways
12.42 CCND1 HRAS IFNA2 TP53
6
Show member pathways
12.35 CCND1 CDKN2A EGFR HRAS TP53
7
Show member pathways
12.33 CCND1 EGFR HRAS TP53
8 12.27 CCND1 CDKN2A HRAS TP53
9 12.24 CCND1 CDKN2A EGFR HRAS TP53
10
Show member pathways
12.18 CCND1 EGFR HRAS IFNA2
11 12.14 CCND1 EGFR HRAS TP53
12 12.13 CCND1 CDKN2A HRAS TP53
13
Show member pathways
12.08 CCND1 EGFR HRAS TP53
14 12.07 CCND1 EGFR TP53
15 12.03 CCND1 EGFR TP53
16
Show member pathways
12 CCND1 EGFR HRAS
17 11.98 CCND1 CDKN2A HRAS TP53
18
Show member pathways
11.97 CCND1 EGFR HRAS
19 11.95 APP CCND1 TP53
20 11.94 CCND1 CDKN2A TP53
21
Show member pathways
11.93 EGFR HRAS TP53
22
Show member pathways
11.93 CCND1 EGFR HRAS
23 11.89 CCND1 EGFR TP53
24 11.88 EGFR HRAS IFNA2 TP53
25 11.86 CCND1 HRAS TP53
26 11.81 CDKN2A HRAS TP53
27 11.77 CCND1 CDKN2A HRAS TP53
28 11.74 EGFR HRAS IFNA2
29
Show member pathways
11.74 CCND1 CDKN2A EGFR HRAS TP53
30 11.55 EGFR HRAS TP53
31
Show member pathways
11.49 CCND1 EGFR HRAS
32 11.46 APP CCND1 TP53
33 11.4 CCND1 CDKN2A EGFR HRAS TP53
34 11.27 CCND1 CDKN2A EGFR TP53
35
Show member pathways
11.1 EGFR HRAS
36 11.04 CCND1 HRAS
37 11.01 CDKN2A TP53
38
Show member pathways
11.01 CDKN2A TP53
39 10.88 CCND1 CDKN2A EGFR HRAS TP53
40 10.77 EGFR HRAS

GO Terms for Penile Cancer

Biological processes related to Penile Cancer according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.84 APP CDKN2A HRAS TP53
2 apoptotic process GO:0006915 9.83 APP CDKN2A HRAS IFNA2 TP53
3 cell cycle arrest GO:0007050 9.72 CDKN2A HRAS TP53
4 response to oxidative stress GO:0006979 9.7 APP EGFR TP53
5 response to organic cyclic compound GO:0014070 9.69 CCND1 EGFR TP53
6 cell aging GO:0007569 9.61 HRAS TP53
7 cellular response to gamma radiation GO:0071480 9.61 HRAS TP53
8 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.59 APP EGFR
9 cellular senescence GO:0090398 9.58 CDKN2A HRAS
10 response to X-ray GO:0010165 9.58 CCND1 TP53
11 positive regulation of G2/M transition of mitotic cell cycle GO:0010971 9.57 APP CCND1
12 regulation of long-term neuronal synaptic plasticity GO:0048169 9.56 APP HRAS
13 Ras protein signal transduction GO:0007265 9.5 CDKN2A HRAS TP53
14 positive regulation of superoxide anion generation GO:0032930 9.49 CRP EGFR
15 replicative senescence GO:0090399 9.48 CDKN2A TP53
16 mitotic G1 DNA damage checkpoint GO:0031571 9.46 CCND1 TP53
17 positive regulation of protein phosphorylation GO:0001934 9.46 APP CCND1 EGFR HRAS
18 amyloid fibril formation GO:1990000 9.4 APP CDKN2A
19 astrocyte activation GO:0048143 9.37 APP EGFR
20 positive regulation of gene expression GO:0010628 9.35 APP CDKN2A CRP HRAS TP53
21 response to UV-A GO:0070141 9.26 CCND1 EGFR
22 positive regulation of phosphorylation GO:0042327 8.8 APP EGFR IFNA2
23 positive regulation of transcription by RNA polymerase II GO:0045944 10 APP CDKN2A EGFR HRAS TP53

Molecular functions related to Penile Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.26 CCND1 CDKN2A EGFR TP53
2 enzyme binding GO:0019899 8.92 APP CCND1 EGFR TP53

Sources for Penile Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....